Surfaxin to Prevent RDS

May 2012
Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-8
The article offers information that Surfaxin, a peptide surfactant, from Discovery Laboratories Inc. has been approved for prevention of high-risk premature infants with respiratory distress syndrome (RDS).


Related Articles

  • Possible treatment for RDS.  // British Medical Journal;8/12/1978, Vol. 2 Issue 6135, p455 

    Examines the treatment for respiratory distress syndrome (RDS). Main component of natural surfactant; Cause of RDS; Transition temperature of dipalmitoyl phosphatidylcholine.

  • Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Baroutis, Georgios; Kaleyias, Joseph; Liarou, Theodora; Papathoma, Eugenia; Hatzistamatiou, Zoe; Costalos, Christos // European Journal of Pediatrics;2003, Vol. 162 Issue 7/8, p476 

    .The aim of the study was to compare the treatment regimen of three natural surfactants of different extraction and formulation (Alveofact [Surfactant A = SA], Poractant [Surfactant B = SB] and Beractant [Surfactant C = SC]) in neonatal respiratory distress syndrome (RDS). Premature infants of...

  • Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. Tubman, T.R.J.; Halliday, H.L.; Normand, C. // BMJ: British Medical Journal (International Edition);10/13/90, Vol. 301 Issue 6756, p842 

    Estimates the cost of porcine surfactant treatment for babies with severe respiratory distress syndrome in Belfast, Northern Ireland. Citation om complications of the treatment; Provision of surfactants by the Karolinska Institute; Tendency of these babies to stay long in hospitals.

  • Temple speaks out on ethical issues with pediatric trial. Dickinson, James G. // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p32 

    Focuses on the ethical implications of conducting the placebo-control trial of surfactants in Latin America. High mortality rate of premature newborn infants; Treatment of the respiratory distress syndrome in premature neonates; Availability of marketed surfactants in the country.

  • Placebo Effect.  // Pharmaceutical Executive;Jul2001, Vol. 21 Issue 7, p106 

    Reports on the criticism against the plan of Discovery Laboratories to test Surfaxin, a treatment for respiratory distress syndrome, in Latin America. Action taken by the company in response to the criticism.

  • Urine Output in Infants with Respiratory Distress Syndrome Treated with Surfactant. Hamdan, A. H.; Shaw, N. J. // Clinical Pediatrics;Jul2000, Vol. 39 Issue 7, p421 

    Provides information on a study which determined the time and onset of diuresis in infants with respiratory distress syndrome treated with surfactant. Patients and methods; Presentation of results; Discussion of findings; Conclusions.

  • Comparison of Curosurf versus Surfacten in the Treatment of Respiratory Distress Syndrome. Jeong Nam Kim; Eun Jung Shim // Neonatal Medicine;May2013, Vol. 20 Issue 2, p207 

    Purpose: The goal of this study was to compare the effects of treatment of newborn babies with two different surfactants, Curosurf® and Surfacten®. Methods: We retrospectively reviewed the medical records from 2007 to 2009 and divided the patients into two groups: those who received...

  • Surfactant replacement and open lung concept -- Comparison of two treatment strategies in an experimental model of neonatal ARDS. Hilgendorff, Anne; Aslan, Ece; Schaible, Thomas; Gortner, Ludwig; Baehner, Thorsten; Ebsen, Michael; Kreuder, Jochen; Ruppert, Clemens; Guenther, Andreas; Reiss, Irwin // BMC Pulmonary Medicine;2008, Vol. 8, Special section p1 

    Background: Several concepts of treatment in neonatal ARDS have been proposed in the last years. The present study compared the effects of open lung concept positive pressure ventilation (PPVOLC) with a conventional ventilation strategy combined with administration of two different surfactant...

  • Early Surfactant Therapy With Nasal Continuous Positive Airway Pressure or Continued Mechanical Ventilation in Very Low Birth Weight Neonates With Respiratory Distress Syndrome. Najafian, Bita; Fakhraie, Seyed Hasan; Afjeh, Seyed Abulfazl; Kazemian, Mohammad; Shohrati, Majid; Saburi, Amin // Iranian Red Crescent Medical Journal;Apr2014, Vol. 16 Issue 4, p1 

    Background: Various strategies have been suggested for the treatment of respiratory distress syndrome (RDS). Objectives: The aim of this study was to compare the efficacies of two common methods of RDS management among neonates with low birth weight. Patients and Methods: A cohort study was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics